SLL: Clinical Trials

2 trials for SLL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 11Completed 1

Follow SLL: new trials by email Literature Review of SLL trials Research Report on SLL

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
rituximab, bortezomib, cladribine - Lymphoma, Mantle Cell Lymphoma
Phase 2CompletedUniversity of Arizona242009-07-072019-12-30
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
veltuzumab - NHL, Lymphoma, Non-Hodgkin
Phase 1 / Phase 2CompletedGilead Sciences322008-01-012021-08-16

Narrower conditions

Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma, Follicular (2)  ·  Dendritic Cell Sarcoma, Interdigitating (1)  ·  Leukemia (1)  ·  Leukemia, Prolymphocytic (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Waldenstrom Macroglobulinemia (1)

Broader conditions

Chronic Disease (2)  ·  Disease Attributes (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Leukemia, B-Cell (2)  ·  Leukemia, Lymphoid (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Blood Protein Disorders (1)

Interventions

Bortezomib (1)  ·  Cladribine (1)  ·  Rituximab (1)  ·  veltuzumab (1)

Sponsors

Gilead Sciences (1)  ·  University of Arizona (1)

Countries

United States (2)

Top investigators

Daniel O. Persky, MD (1)  ·  William Wegener, MD, PhD (1)

Results publications

PMID 21173095, PMID 26389849, PMID 29056470

NIH funding

P30CA023074 (1)